ERBB2 and breast carcinoma: In comparison with the meta-analyses by Shi et al. [6] and Kariyanna et al. [7], which focused on broader cancer populations, our study is specifically centered on breast cancer patients, a group with heightened susceptibility to cardiotoxicity due to the cumulative effects of anthracyclines, often combined with radiotherapy or HER2-targeted therapies [47,48].